Practices affEcting macitentan and selexipag patient persistence Rates utilizing pulmonary arterial hypertension clinical Site and patIent perSpecTives (PERSIST): a US qualitative analysis

Oksana A Shlobin; Gary Bruce; Gabriela Gomez-Rendon; Martha Kingman; Mohammad Rahman; Frances Rogers; Sean Studer; Tobore Tobore; Colleen McEvoy

doi:10.1002/pul2.12441

Practices affEcting macitentan and selexipag patient persistence Rates utilizing pulmonary arterial hypertension clinical Site and patIent perSpecTives (PERSIST): a US qualitative analysis

Pulm Circ. 2024 Oct 11;14(4):e12441. doi: 10.1002/pul2.12441. eCollection 2024 Oct.

Authors

Oksana A Shlobin¹, Gary Bruce², Gabriela Gomez-Rendon³, Martha Kingman⁴, Mohammad Rahman³, Frances Rogers⁵, Sean Studer³, Tobore Tobore³, Colleen McEvoy⁶

Affiliations

¹ Advanced Lung Disease and Transplant Program Inova Fairfax Hospital Falls Church Virginia USA.
² Patient author Dallas Texas USA.
³ Actelion Pharmaceuticals US, Inc., a Johnson & Johnson company Titusville New Jersey USA.
⁴ Internal Medicine University of Texas Southwestern Medical Center Dallas Texas USA.
⁵ Temple University Hospital, Heart and Vascular Institute Philadelphia Pennsylvania USA.
⁶ Division of Pulmonary and Critical Care Medicine, Department of Medicine Washington University School of Medicine St. Louis Missouri USA.

Abstract

This real-world study explored factors affecting persistence with macitentan and selexipag treatment from the perspective of 23 healthcare professionals (HCPs) and 134 patients with pulmonary arterial hypertension between 2019 and 2022. Continuous patient/HCP communication and education were key drivers of persistence, as were early discussion and management of side effects.

Keywords: healthcare professional discussion tool; patient perspectives; pulmonary hypertension.